Cooley M&A

FEBRUARY 8, 2018

No longer just “acquihires,” today’s innovation-driven acquisition is focused on talent retention. Approval of gross-ups in connection with a transaction typically involves a prior negotiation with the buyer. See ABA Private Target Mergers & Acquisitions Deal Point Study for 2016-2017.

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

Peak Frameworks

SEPTEMBER 19, 2023

For example, while a pharmaceutical company focused solely on shareholder value might prioritize high-margin drugs for rare conditions, a stakeholder-oriented approach might consider affordability and broader societal health needs , as seen with Gilead's approach to its HIV medications.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. We can no longer give this advice. The Merger Agreement.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Sun Acquisitions

AUGUST 22, 2024

To mitigate these risks and build more resilient supply chains, companies are increasingly turning to strategic mergers and acquisitions (M&A). Larger, consolidated companies can negotiate better terms with suppliers, secure more favorable contracts, and reduce per-unit production costs.

M&A 52

M&A Management Mergers and Acquisitions Food 52

Cooley M&A

APRIL 7, 2017

The court agreed with Gilead, based primarily on a review of the parties’ drafting and negotiating history, which was corroborated by the parties’ contemporaneous statements made after the European Commission approved the deal. Throughout the trial, it was evident that the word had various meanings during the negotiations.

Mergers and Acquisitions 40

Mergers and Acquisitions Negotiation Pharmaceutical IT 40

Cooley M&A

JUNE 10, 2020

The panel kicked off with a discussion about what types of assets pharmaceutical buyers tend to gravitate toward – both from a general market perspective and from the more specific view of Horizon. Acquisition transaction vs. partnership opportunity. Key areas of interest for buyers and investors.

M&A 40

M&A Medical Acquisitions Business 40

Global Newswire by Notified: M&A

DECEMBER 7, 2023

According to the new negotiated terms, the Company will acquire 100% of the Target Company and will establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into the Target Company (the “Acquisition”). TEL AVIV, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd.

Negotiation 45

Negotiation Pharmaceutical Acquisitions Shares 45

Cooley M&A

JULY 10, 2017

The acquisition agreement should include safeguards to provide the buyer with advance notice of a proposed transfer and strong consent rights over the offering process and disclosure provided to the transferee. acquisitions of pharmaceutical products with clinical, regulatory and/or net sales milestones). Subsequent transfer.

Securities 52

Securities IT Investors M&A 52

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 billion , Acceleron Pharma’s agreement to sell to Merck for $11.5 With COVID?19

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Devensoft

AUGUST 24, 2023

By melding the proficiencies, assets, and potentials residing within distinct business sectors or entities under a single organizational umbrella, the practice of mergers and acquisitions unveils dormant possibilities, propels inventive evolution, and champions the delivery of unparalleled outcomes.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

FEBRUARY 15, 2017

The continued publicity and political focus on drug pricing has created uncertainty in valuing specialty pharmaceutical and biotech companies. Negotiating Anti-Reliance Language. Innovation Pressures Fuel M&A. Uncertain Times Cast Focus on Deal Certainty. Rep & Warranty (R&W) Insurance is Here. Appraisal Risks Factor High.

M&A 40

M&A IPO Pharmaceutical Valuation 40

Cooley M&A

JANUARY 21, 2022

Amy Klobuchar of Minnesota in February, seeks to give the FTC more power to block mergers and acquisitions. 1 CALERA would also shift the burden to companies to affirmatively prove that their merger or acquisition would not harm competition. Congress targets pharmaceutical industry pricing and business practices.

Mergers and Acquisitions 40

Mergers and Acquisitions Mergers Pharmaceutical IT 40

Cooley M&A

JANUARY 18, 2017

Following the results of the 2016 election, there is a higher likelihood that the Standard Merger and Acquisition Reviews Through Equal Rules Act (“SMARTER Act”) will become law. The potential of significantly increased penalties will likely bring parties to the negotiating table.

Mergers and Acquisitions 52

Mergers and Acquisitions Pharmaceutical Mergers Food 52